2. Academic Validation
  3. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

  • Phytomedicine. 2010 Dec 15;18(1):11-5. doi: 10.1016/j.phymed.2010.09.001.
Desmond Kwok-Po Hau 1,  Guo-Yuan Zhu,  Alexander Kai-Man Leung,  Raymond Siu-Ming Wong,  Gregory Yin-Ming Cheng,  Paul Bo-San Lai,  Sze-Wai Tong,  Fung-Yi Lau,  Kit-Wah Chan,  Wai-Yeung Wong,  Kim-Hung Lam,  Chor-Hing Cheng,  Filly Cheung,  Chung-Hin Chui,  Roberto Gambari,  David Wang-Fun Fong
Affiliations

Affiliation

  • 1 Research and Development Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
PMID: 21036022 DOI: 10.1016/j.phymed.2010.09.001
Abstract

We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15 mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.

Figures
Products